ClinicalTrials.gg
CompletedNCT02791490Updated Feb 28, 2019Results posted

A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

A Phase 3 interventional study of Sitagliptin and Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
458
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
37th of 197
458 · median 102
Started
2016
with 10 others
Phase 3
74 of 198
none open now
Registered
170th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 37th largest by enrollment of the 197 interventional ones that give a count, is one of 11 that started in 2016, is one of 74 in phase 3, and was the 170th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is designed to evaluate, in adult participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on sub-maximal metformin mono-therapy (1000 mg/day), the effect of up-titration of metformin plus the addition of sitagliptin compared to up-titration of metformin alone on glycemic control. The primary hypothesis of this study is that up-titration of metformin to 2000 mg/day (1000 mg/twice a day) plus the addition of sitagliptin 100 mg/day provides greater reduction in hemoglobin A1C (A1C) compared to metformin up-titration alone. Another primary objective of this study is to evaluate the safety and tolerability of this treatment.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants with T2DM in accordance with American Diabetes Association (ADA) guidelines
  • Meet one of the following criteria:

    1. Be on stable Met-IR monotherapy 1000 mg/day for ≥8 weeks with a Screening ≥7.5% and ≤11.0%.

      OR

    2. Be on stable Met-XR monotherapy 1000 mg/day for ≥8 weeks with a Screening A1C ≥7.5% and ≤11.0%.

      OR

    3. Not on any anti-hyperglycemic agent (AHA) for ≥8 weeks (≥12 weeks if previously taking thiazolidinediones) with a Screening A1C ≥8.5% and ≤12.0%.

      OR

    4. Be on stable monotherapy with a sulfonylurea, a glinide, or an α-glucosidase inhibitor for ≥8 weeks with a Screening A1C ≥7.5% and ≤11.0%.
  • A (BMI) ≥18.0 kg/m2.
  • Is a male or a female not of (defined as one who is or has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening visit). If participant is a female of reproductive potential, must agree to remain abstinent from heterosexual activity or agrees to use (or have her partner use) acceptable to prevent pregnancy while receiving blinded study drug and for 14 days after the last dose of blinded study drug

Exclusion criteria

Exclusion Criteria:

  • Has a history of type 1 diabetes mellitus or a history of ketoacidosis or has a history of secondary causes of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant).
  • A known or intolerance to any DPP-4 inhibitor. A known hypersensitivity or intolerance to metformin, including participants who were previously unable to tolerate metformin at a dose >1000 mg/day or who have evidence of intolerance to the dose of metformin they are currently taking.
  • Has been treated with any of the following agents within 8 weeks (12 weeks for thiazolidinediones) of study participation:

    1. Insulin of any type (except for short-term use [i.e., ≤7 days] during concomitant illness or other stress)
    2. DPP-4 inhibitor
    3. Pioglitazone or rosiglitazone (thiazolidinediones)
    4. Glucagon-like peptide-1 receptor (GLP-1R) agonists
    5. Sodium glucose co-transporter 2 (SGLT2) inhibitors
    6. Bromocriptine (Cycloset™)
    7. Colesevelam (Welchol™)
    8. Any other AHA with the exception of protocol-approved agents
  • Intends to initiate weight loss medication during the study period
  • Has undergone bariatric surgery within 12 months of Screening visit
  • Has started a weight loss medication or a medication associated with weight changes within the prior 12 weeks
  • A history of myocardial infarction, unstable angina, arterial revascularization, stroke, , functional class III-IV heart failure, or severe peripheral vascular disease (e.g., claudication with minimal activity, a nonhealing ischemic ulcer, or disease which is likely to require surgery or angioplasty) within 3 months of study participation
  • A history of ≤5 years prior to study participation (i.e., the diagnosis occurred, or any evidence of residual or recurrent disease occurred, within the past 5 years), except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer. Note: A patient with any history of melanoma, leukemia, lymphoma, or renal cell carcinoma is excluded.
  • Has (HIV)

    1. with AIDS related complications, or
    2. has not been on a stable anti-retroviral regimen for >6 months, or
    3. has progressive disease, or
    4. using agents associated with glucose intolerance such as nucleoside reverse transcriptase inhibitors (NRTIs) such as azidothymidine (AZT), didanosine (ddI), and stavudine (d4T).
  • Is on or likely to require treatment for ≥14 consecutive days or repeated courses of pharmacologic doses of .
  • Has undergone a major surgical procedure within 12 weeks prior to signing the form (ICF) or has major surgery planned during the trial.
  • Currently participating, or has participated, in a study in which the participant received an compound or used an investigational device within the prior 12 weeks of signing informed consent or is not willing to refrain from participating in another study.
  • Is pregnant or breast-feeding, has a positive urine pregnancy test, or is planning to conceive or donate eggs during the study, including 14 days following the last dose of blinded investigational product.
  • A recent history of alcohol or drug abuse (within 3 years) or is a user of recreational or illicit drugs at the time of screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
458 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Participants will receive sitagliptin 100 mg once daily for 20 weeks. They will also receive immediate-release metformin (Met-IR), which will be titrated from a baseline dose of 1000 mg/day (500 mg/twice a day \[b.i.d.\]) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.

    Drug: Sitagliptin · Drug: Metformin IR

  • Placebo comparator
    Placebo

    Participants will receive placebo matching sitagliptin once daily for 20 weeks. They will also receive Met-IR, which will be titrated from baseline dose of 1000 mg/day (500 mg/b.i.d.) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.

    Drug: Placebo · Drug: Metformin IR

Interventions

  • Oral tablet, 100 mg, once daily at approximately the same time each day

    Also known as: JANUVIA®, TESAVEL®, XELEVIA®, RISTABEN®

  • DrugPlacebo

    Oral tablet, once daily at approximately the same time each day

  • All participants will take Met-IR as background medication. Initially, they will take 1 x 500 mg tablet Met-IR b.i.d. (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR b.i.d. (2000 mg/day).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C at Week 20

    Hemoglobin A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. The change from baseline represents the Week 20 A1C value minus the Week 0 (baseline) A1C value.

    Time frame: Baseline and Week 20

  2. Percentage of Participants Who Experienced at Least One Adverse Event (AE)

    An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to 22 weeks

  3. Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to 20 weeks

Secondary outcomes

  1. Percentage of Participants With Hemoglobin A1C <7% at Week 20

    Hemoglobin A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

    Time frame: Week 20

  2. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20

    Plasma glucose was measured on a fasting basis and is expressed as mg/dL. Blood was drawn predose on Day 1 and after 20 weeks of treatment to determine change in FPG levels. The change from baseline represents the Week 20 FPG value minus the Week 0 (baseline) FPG value.

    Time frame: Baseline and Week 20

  3. Percentage of Participants With Hemoglobin A1C ≥8.5% at Baseline That Attained A1C Goal of <7% at Week 20

    Hemoglobin A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

    Time frame: Baseline and Week 20

  4. Percentage of Participants Receiving Glycemic Rescue Therapy

    Participants who met pre-specified criteria for glycemic rescue received appropriate rescue therapy. The choice of anti-hyperglycemic rescue agent, dose, and regimen was directed by the investigator, as clinically appropriate.

    Time frame: Up to 20 weeks

07

Results

Posted Feb 28, 2019

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinPlacebo
Started229229
Completed226221
Not completed38
Withdrew: Lost to follow-up12
Withdrew: Withdrawal by subject26

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C at Week 20

Hemoglobin A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. The change from baseline represents the Week 20 A1C value minus the Week 0 (baseline) A1C value.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · A1C (%)
Change From Baseline in Hemoglobin A1C at Week 20
A1C (%)SitagliptinPlacebo
Change From Baseline in Hemoglobin A1C at Week 20-1.10 (-1.28 to -0.93)-0.69 (-0.88 to -0.51)
Statistical analysis
  • Sitagliptin vs Placebo · Longitudinal Data Analysis · p = <0.001 · Difference in least squares means: -0.41 · 95% CI -0.59 to -0.23
PrimaryPercentage of Participants Who Experienced at Least One Adverse Event (AE)

An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to 22 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced at Least One Adverse Event (AE)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants Who Experienced at Least One Adverse Event (AE)44.145.9
Statistical analysis
  • Sitagliptin vs Placebo · Miettinen and Nurminen method · Difference in % vs placebo: -1.7 · 95% CI -10.8 to 7.4
PrimaryPercentage of Participants Who Discontinued Study Drug Due to an Adverse Event

An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to 20 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event
Percentage of participantsSitagliptinPlacebo
Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event0.90.0
SecondaryPercentage of Participants With Hemoglobin A1C <7% at Week 20

Hemoglobin A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

Time frame:
Week 20
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin A1C <7% at Week 20
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With Hemoglobin A1C <7% at Week 2028.816.6
Statistical analysis
  • Sitagliptin vs Placebo · Miettinen and Nurminen method · p = 0.002 · Relative risk: 1.7 · 95% CI 1.2 to 2.5
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 20

Plasma glucose was measured on a fasting basis and is expressed as mg/dL. Blood was drawn predose on Day 1 and after 20 weeks of treatment to determine change in FPG levels. The change from baseline represents the Week 20 FPG value minus the Week 0 (baseline) FPG value.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20
mg/dLSitagliptinPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20-29.3 (-37.5 to -21.1)-16.9 (-25.2 to -8.6)
Statistical analysis
  • Sitagliptin vs Placebo · Longitudinal Data Analysis · p = 0.002 · Difference in least squares means: -12.4 · 95% CI -20.2 to -4.6
SecondaryPercentage of Participants With Hemoglobin A1C ≥8.5% at Baseline That Attained A1C Goal of <7% at Week 20

Hemoglobin A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

Time frame:
Baseline and Week 20
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin A1C ≥8.5% at Baseline That Attained A1C Goal of <7% at Week 20
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With Hemoglobin A1C ≥8.5% at Baseline That Attained A1C Goal of <7% at Week 2015.65.7
SecondaryPercentage of Participants Receiving Glycemic Rescue Therapy

Participants who met pre-specified criteria for glycemic rescue received appropriate rescue therapy. The choice of anti-hyperglycemic rescue agent, dose, and regimen was directed by the investigator, as clinically appropriate.

Time frame:
Up to 20 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Receiving Glycemic Rescue Therapy
Percentage of participantsSitagliptinPlacebo
Percentage of Participants Receiving Glycemic Rescue Therapy1.33.1

Adverse events

Collected over Up to 22 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin0/229 (0%)3/229 (1.3%)18/229 (7.9%)
Placebo0/229 (0%)4/229 (1.7%)11/229 (4.8%)
Most frequent serious events
Most frequent serious events
EventSitagliptinPlacebo
Acute myocardial infarctionCardiac disorders1/2290/229
Myocardial ischaemiaCardiac disorders0/2291/229
Fatty liver alcoholicHepatobiliary disorders1/2290/229
Stab woundInjury, poisoning and procedural complications0/2291/229
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/2291/229
Acute kidney injuryRenal and urinary disorders1/2290/229
MetrorrhagiaReproductive system and breast disorders0/2291/229
ProstatitisReproductive system and breast disorders1/2290/229
Most frequent other events
Most frequent other events
EventSitagliptinPlacebo
DiarrhoeaGastrointestinal disorders18/22911/229

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SitagliptinPlaceboTotal
Mean55.6 ± 10.555.3 ± 10.455.5 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinPlaceboTotal
Female139136275
Male9093183
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SitagliptinPlaceboTotal
Hispanic or Latino147151298
Not Hispanic or Latino7870148
Unknown or Not Reported4812
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SitagliptinPlaceboTotal
American Indian or Alaska Native232750
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American8715
White167155322
More than one race313970
Unknown or Not Reported000
Hemoglobin A1C (%)
Hemoglobin A1C (%)(Percentage of glycosylated hemoglobin)SitagliptinPlaceboTotal
Mean8.6 ± 0.98.7 ± 1.08.7 ± 0.9
Fasting Plasma Glucose
Fasting Plasma Glucose(mg/dL)SitagliptinPlaceboTotal
Mean181.7 ± 41.6184.4 ± 44.7183.0 ± 43.2
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Frias JP, Zimmer Z, Lam RLH, Amorin G, Ntabadde C, Iredale C, O'Neill EA, Engel SS, Kaufman KD, Makimura H, Crutchlow MF. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. Diabetes Obes Metab. 2019 May;21(5):1128-1135. doi: 10.1111/dom.13626. Epub 2019 Feb 17. PubMed 30609212 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Feb 2018, 19 months.

Results were first posted in Feb 2019, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 19 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2016
First posted
Jun 6, 2016
StartActual
Jun 16, 2016
Primary completionActual
Feb 1, 2018
CompletionActual
Feb 1, 2018
Results first posted
Feb 28, 2019
Last update
Feb 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02791490
Responsible party
Sponsor
First posted
Jun 6, 2016
Start date
Jun 16, 2016
Primary completion
Feb 1, 2018
Completion
Feb 1, 2018
Results posted
Feb 28, 2019
Last update
Feb 28, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion